(Q24245639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

title

Atovaquone-proguanil for treating uncomplicated malaria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

A Osei-Akoto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

L Orton

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S P O Owusu-Ofori

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

19 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

CD004529

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone and proguanil for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Multiresistant falciparum malaria cured using atovaquone and proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Malarone-donation programme in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Malarone-donation programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Increasing antimalarial drug resistance in Uganda and revision of the national drug policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Malarone-donation programme in Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Sustainability, affordability, and equity of corporate drug donations: the case of Malarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

A political analysis of corporate drug donations: the example of Malarone in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

21 January 2018

12 December 2020

Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD004529.PUB2

21 January 2018

12 December 2020

A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia

1 reference

12 December 2020

Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand

1 reference

12 December 2020

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group

1 reference

12 December 2020

Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial.

1 reference

12 December 2020

Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru

1 reference

12 December 2020

A public-private partnership for malaria control: lessons from the Malarone Donation Programme.

1 reference

12 December 2020

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

12 December 2020

Clinical pharmacology of atovaquone and proguanil hydrochloride

1 reference

12 December 2020

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

12 December 2020

Atovaquone and proguanil for the treatment of malaria in Brazil.

1 reference

12 December 2020

Distinguishing Plasmodium falciparum treatment failures from reinfections by restrictions fragment length polymorphism and polymerase chain reaction genotyping

1 reference

12 December 2020

10.1002/14651858.CD004529.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16235366%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

16235366

1 reference